title: [Application of regional arterial infusion chemotherapy in short-term neoadjuvant chemotherapy for advanced gastric cancer].
abstract: OBJECTIVE
  To explore the feasibility of short-term neoadjuvant chemotherapy (NACT) in patients with advanced gastric cancer (AGC), and to compare clinical efficacy of short-term neoadjuvant chemotherapy with different ways.
  
  
  METHODS
  Clinical data of 310 AGC patients treated with one course of NACT using EOF regimen(epirubicin, oxaliplatin and fluorouracil plus calcium folinate) in our hospital from January 2008 to December 2011 were retrospectively analyzes. Efficacy was compared between regional arterial infusion chemotherapy and intravenously chemotherapy.
  
  
  RESULTS
  All the 310 AGC patients completed one course of NACT and none was interrupted by adverse events. Postoperative pathological remission rate was 33.9% (105/310) and 5 patients (1.6%) had complete pathological remission. The pathologic response rate in the regional arterial infusion chemotherapy group was higher than that in the intravenously chemotherapy group(42.4% vs. 23.6%, P = 0.001). Multivariate analysis revealed that chemotherapy method(HR=1.827, 95% CI:1.006-3.316, P = 0.048) was associated with significantly higher pathologic response.
  
  
  CONCLUSIONS
  Pathological response rate is quite low following short-term NACT. Regional arterial infusion chemotherapy with short-term NACT can improve the pathological response rate of advanced gastric cancer.
authors.affiliation: Department of Surgical Oncology, The Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing 210029, China. checheng00@163.com.
authors.forename: Zhenfeng
authors.initials: Z
authors.lastname: Wu
authors.forename: Wenqiang
authors.initials: W
authors.lastname: Zhu
authors.forename: Qinhong
authors.initials: Q
authors.lastname: Cao
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Chen
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Wu
authors.forename: Che
authors.initials: C
authors.lastname: Chen
authors.forename: Zhe
authors.initials: Z
authors.lastname: Xu
authors.forename: WeiSu
authors.initials: W
authors.lastname: Li
authors.forename: Xuequan
authors.initials: X
authors.lastname: Yao
authors.forename: Fukun
authors.initials: F
authors.lastname: Liu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D015251:Epirubicin; D005472:Fluorouracil; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D012074:Remission Induction; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D015251:Epirubicin; D002955:Leucovorin; D005472:Fluorouracil